Erasca (ERAS) to Release Earnings on Wednesday

Erasca (NASDAQ:ERAS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

Erasca (NASDAQ:ERAS - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. During the same period last year, the business earned ($0.20) earnings per share. On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Erasca Price Performance

NASDAQ ERAS opened at $1.25 on Wednesday. The company has a market cap of $354.11 million, a P/E ratio of -1.51 and a beta of 1.12. Erasca has a 12 month low of $1.01 and a 12 month high of $3.45. The company has a 50-day moving average of $1.35 and a 200-day moving average of $2.02.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ERAS. Morgan Stanley reaffirmed an "overweight" rating and set a $4.00 price target on shares of Erasca in a research report on Friday, March 7th. Bank of America upgraded Erasca from a "neutral" rating to a "buy" rating and set a $5.00 price objective for the company in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Erasca in a report on Wednesday, April 30th. The Goldman Sachs Group lowered their price target on Erasca from $3.50 to $3.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, Raymond James began coverage on Erasca in a report on Wednesday, March 26th. They issued an "outperform" rating and a $5.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $4.83.

About Erasca

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.